Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Pfizer invests $500 million in expanding gene therapy facility

Pfizer Inc. is investing $500 million to expand a manufacturing facility in Sanford, North Carolina, that plays a central role in the company’s efforts to become a major player in gene therapy.

Read More »

Roche acquires Spark Therapeutics for $4.3 billion

Roche is buying U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion after developments in this area convinced the Swiss drugmaker to “step up”, Chief Executive Severin Schwan said.

Read More »

U.S. FDA expands approval of Roche hemophilia drug

U.S. regulators approved expanded use of Roche’s drug Hemlibra to include almost all patients with hemophilia A.

Read More »

uniQure, Bioverativ Unveil Positive Data for Hemophilia B and Hemophilia A Patients

Clinical data suggests that uniQure’s AAV5 gene therapy may be viable treatments for 97 percent of hemophilia B patients.

Read More »

11 Most Innovative Life Science Companies in the World

Fast Company recently published The World’s 50 Most Innovative Companies 2018, topping off its edition of the top 350 most innovative companies. Here is a look at the life science companies that made the list.

Read More »

Sanofi to buy U.S. hemophilia group Bioverativ

Paris-based Sanofi has acquired Waltham, Mass.-based Bioverativ for about $11.6 billion.

Read More »

Spark, Pfizer’s Gene Therapy Hemophilia B Drug Stuns in Trial

Philadelphia-based Spark Therapeutics, with its partner Pfizer, published interim data from its Phase I/II clinical trial of a gene therapy for hemophilia B in The New England Journal of Medicine.

Read More »

Sangamo Scores Bragging Rights for First-in-Human Gene Editing Trial

Barely a week after announcing it was moving into a new corporate headquarters, Sangamo Therapeutics announced that the company has dosed the first patient in its Phase I/II gene therapy trial.

Read More »

Patient Death Forces Alnylam to Suspend Dosing in Hemophilia Trial, Stock Plunges

Alnylam Pharmaceuticals indicated that the company suspended its Phase II trial of fitusiran for hemophilia A after a patient died from a thrombotic event, pending further investigation.

Read More »

Troubled Dimension Therapeutics Sold in All-Stock Deal

Shares of beleaguered Dimension Therapeutics Inc. soared more than 160 percent in premarket trading after gene therapy company Regenxbio Inc. announced its acquisition via an all-stock deal.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!


Ad Right Bottom